Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription

Articles published in
BMC Cancer
    June 2018
  1. LIU H, He W, Wang B, Xu K, et al
    MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    BMC Cancer. 2018;18:659.
    >> Share

  2. LIU Y, Wang H, Zhong J, Wu C, et al
    Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis.
    BMC Cancer. 2018;18:642.
    >> Share

    May 2018
  3. KWON WA, Joung JY, Lim J, Oh CM, et al
    Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea.
    BMC Cancer. 2018;18:617.
    >> Share

  4. XIE H, Zhu Y, Zhang J, Liu Z, et al
    B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    BMC Cancer. 2018;18:590.
    >> Share

    February 2018
  5. PULIDO M, Roubaud G, Cazeau AL, Mahammedi H, et al
    Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
    BMC Cancer. 2018;18:194.
    >> Share

  6. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Oxidative damage and response to Bacillus Calmette-Guerin in bladder cancer cells expressing sialyltransferase ST3GAL1.
    BMC Cancer. 2018;18:198.
    >> Share

    December 2017
  7. ZHANG Z, Zhang G, Gao Z, Li S, et al
    Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
    BMC Cancer. 2017;17:861.
    >> Share

    November 2017
  8. HUEBNER D, Rieger C, Bergmann R, Ullrich M, et al
    An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
    BMC Cancer. 2017;17:790.
    >> Share

  9. TAN WS, Feber A, Dong L, Sarpong R, et al
    DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
    BMC Cancer. 2017;17:767.
    >> Share

  10. TOLKACH Y, Stahl AF, Niehoff EM, Zhao C, et al
    YRNA expression predicts survival in bladder cancer patients.
    BMC Cancer. 2017;17:749.
    >> Share

    September 2017
  11. NEUZILLET Y, Chapeaublanc E, Krucker C, De Koning L, et al
    IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
    BMC Cancer. 2017;17:636.
    >> Share

    June 2017
  12. PENG D, Gong YQ, Hao H, He ZS, et al
    Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.
    BMC Cancer. 2017;17:391.
    >> Share

    May 2017
  13. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    >> Share

  14. FONTEYNE V, Dirix P, Junius S, Rammant E, et al
    Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
    BMC Cancer. 2017;17:308.
    >> Share

    April 2017
  15. KAO YT, Wu CH, Wu SY, Lan SH, et al
    Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells.
    BMC Cancer. 2017;17:277.
    >> Share

  16. LAVERY HJ, Zaharieva B, McFaddin A, Heerema N, et al
    A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.
    BMC Cancer. 2017;17:247.
    >> Share

    March 2017
  17. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
    BMC Cancer. 2017;17:237.
    >> Share

    February 2017
  18. DYSHLOVOY SA, Madanchi R, Hauschild J, Otte K, et al
    The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
    BMC Cancer. 2017;17:93.
    >> Share

    January 2017
  19. BAI Y, Wang X, Yang Y, Tang Y, et al
    Parity and bladder cancer risk: a dose-response meta-analysis.
    BMC Cancer. 2017;17:31.
    >> Share

    November 2016
  20. KONG C, Zhan B, Piao C, Zhang Z, et al
    Overexpression of UNC5B in bladder cancer cells inhibits proliferation and reduces the volume of transplantation tumors in nude mice.
    BMC Cancer. 2016;16:892.
    >> Share

  21. BENHAMOU S, Bonastre J, Groussard K, Radvanyi F, et al
    A prospective multicenter study on bladder cancer: the COBLAnCE cohort.
    BMC Cancer. 2016;16:837.
    >> Share

    January 2016
  22. KAWAHARA T, Furuya K, Nakamura M, Sakamaki K, et al
    Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.
    BMC Cancer. 2016;16:185.
    >> Share

  23. LOPEZ DE MATURANA E, Picornell A, Masson-Lecomte A, Kogevinas M, et al
    Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models.
    BMC Cancer. 2016;16:351.
    >> Share

  24. GARCIA PV, Seiva FR, Carniato AP, de Mello Junior W, et al
    Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    BMC Cancer. 2016;16:422.
    >> Share

  25. LI X, Wang H, Wang J, Chen Y, et al
    Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
    BMC Cancer. 2016;16:578.
    >> Share

  26. OLDENBURG D, Ru Y, Weinhaus B, Cash S, et al
    CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).
    BMC Cancer. 2016;16:713.
    >> Share

  27. ROPERCH JP, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, et al
    Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    BMC Cancer. 2016;16:704.
    >> Share

  28. ANANTHARAMAN A, Friedlander T, Lu D, Krupa R, et al
    Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    BMC Cancer. 2016;16:744.
    >> Share

    January 2015
  29. ZHOU B, Zhang P, Tang T, Liao H, et al
    Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer.
    BMC Cancer. 2015;15:433.
    >> Share

  30. HAYNE D, Stockler M, McCombie SP, Chalasani V, et al
    BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    BMC Cancer. 2015;15:432.
    >> Share

  31. KU JH, Kang M, Kim HS, Jeong CW, et al
    Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis.
    BMC Cancer. 2015;15:447.
    >> Share

  32. LEE JY, Cho KS, Kang DH, Jung HD, et al
    A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging.
    BMC Cancer. 2015;15:566.
    >> Share

  33. ACAR O, Ozkurt E, Demir G, Sarac H, et al
    Determining the origin of synchronous multifocal bladder cancer by exome sequencing.
    BMC Cancer. 2015;15:871.
    >> Share

  34. SMOLENSKY D, Rathore K, Cekanova M
    Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
    BMC Cancer. 2015;15:927.
    >> Share

  35. KIM M, Jeong CW, Kwak C, Kim HH, et al
    Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study.
    BMC Cancer. 2015;15:149.
    >> Share

  36. YEH HH, Tseng YF, Hsu YC, Lan SH, et al
    Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity.
    BMC Cancer. 2015;15:172.
    >> Share

  37. DORES GM, Qubaiah O, Mody A, Ghabach B, et al
    A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010.
    BMC Cancer. 2015;15:185.
    >> Share

  38. LIU W, Qi L, Lv H, Zu X, et al
    MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy.
    BMC Cancer. 2015;15:92.
    >> Share

  39. RETZ M, de Geeter P, Goebell PJ, Matz U, et al
    Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.
    BMC Cancer. 2015;15:455.
    >> Share

    January 2014
  40. CASTELLANO D, Puente J, de Velasco G, Chirivella I, et al
    Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
    BMC Cancer. 2014;14:779.
    >> Share

  41. GREIFE A, Jankowiak S, Steinbring J, Nikpour P, et al
    Canonical Notch signalling is inactive in urothelial carcinoma.
    BMC Cancer. 2014;14:628.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016